The prospective, open-lable, single-arm, single-center clinical study of Apatinib mesylate combined with capecitabine in non-first-line treating patients with recurrent/metastatic triple-negative breast cancer
Latest Information Update: 03 Nov 2016
Price :
$35 *
At a glance
- Drugs Capecitabine (Primary) ; Rivoceranib (Primary)
- Indications Advanced breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- 03 Nov 2016 New trial record